Companies › CanSino Biologics
8 active drug programs in 13 registered trials: 6 Phase 3, 6 Phase 1, 1 Phase 4; Infectious disease; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) Meningococcal polysaccharide conjugate vaccine targeting serogroups A, C, Y, W135 conjugat | – | Phase 4 | Epidemic Meningitis; Meningococcal Meningitis | – |
| PCV13i 13-valent pneumococcal conjugate vaccine | – | Phase 3 | Pneumococcal Infections | Feb 2027 |
| Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Inactivated bacterial toxoids (diphtheria and tetanus) combined with acellular pertussis a | – | Phase 3 | Diphtheria, Tetanus and Acellular Pertussis | – |
| 24-valent pneumococcal polysaccharide conjugate vaccine (CRM197/tetanus toxoid) Pneumococcal polysaccharide conjugate vaccine with CRM197 and tetanus toxoid carriers targ | – | Phase 1 | Streptococcus Pneumoniae Infection | Nov 2026 |
| VLP-Polio low adjuvant dose Recombinant trivalent poliomyelitis vaccine | – | Phase 1 | Poliomyelitis | Dec 2026 |
| Adsorbed Acellular Pertussis (3-Component) Diphtheria-Tetanus-Pertussis-Haemophi Combined vaccine with acellular pertussis toxoid, diphtheria toxoid, tetanus toxoid, Haemo | – | Phase 1 | Diphtheria, Tetanus and Acellular Pertussis | Feb 2029 |
| Ad5-105K Adenovirus serotype 5 vector expressing Mycobacterium tuberculosis antigens | – | Phase 1 | Tuberculosis | – |
| Lyophilized Haemophilus Influenzae Type b Conjugate Vaccine Haemophilus influenzae type b polysaccharide conjugate vaccine | HIB | Phase 1 | Haemophilus Influenzae Type B Infection | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06226714 | ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) | Phase 3 | Meningococcal Meningitis | Infectious disease | Sep 2024 |
| NCT05951725 | Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, | Phase 3 | Diphtheria, Tetanus and Acellular Pertussis | Infectious disease | Apr 2025 |
| NCT06857370 | Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, | Phase 3 | Diphtheria, Tetanus and Acellular Pertussis | Infectious disease | Jan 2026 |
| NCT06857370 | Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, | Phase 3 | Diphtheria, Tetanus and Acellular Pertussis | Infectious disease | Jan 2026 |
| NCT06857370 | Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, | Phase 3 | Diphtheria, Tetanus and Acellular Pertussis | Infectious disease | Jan 2026 |
| NCT05935176 | ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) | Phase 4 | Epidemic Meningitis | Infectious disease | May 2026 |
| NCT06732583 | Ad5-105K | Phase 1 | Tuberculosis | Infectious disease | Aug 2026 |
| NCT06621654 | Lyophilized Haemophilus Influenzae Type b Conjugate Vaccine | Phase 1 | Haemophilus Influenzae Type B Infection | Infectious disease | Oct 2026 |
| NCT07600983 | 24-valent pneumococcal polysaccharide conjugate vaccine (CRM197/tetanus toxoid) | Phase 1 | Streptococcus Pneumoniae Infection | Infectious disease | Nov 2026 |
| NCT06577298 | VLP-Polio low adjuvant dose | Phase 1 | Poliomyelitis | Infectious disease | Dec 2026 |
| NCT06577298 | VLP-Polio low adjuvant dose | Phase 1 | Poliomyelitis | Infectious disease | Dec 2026 |
| NCT07017777 | PCV13i | Phase 3 | Pneumococcal Infections | Infectious disease | Feb 2027 |
| NCT07203755 | Adsorbed Acellular Pertussis (3-Component) Diphtheria-Tetanus-Pertussis-Haemophi | Phase 1 | Diphtheria, Tetanus and Acellular Pertussis | Infectious disease | Feb 2029 |
–
Serum Institute of India Anhui Zhifei Longcom Biologic Pharmacy LimmaTech Biologics MAXVAX Biotechnology Limited Liability Company SK Bioscience
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.